Adage Capital Partners’s Nexvet Biopharma plc Ordinary Shares NVET Stock Holding History

Adage Capital Partners’s Portfolio NVET Stock Details NVET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-795,000	Closed	-$5.32M	–	782
2017 Q2	$5.32M	Hold	795,000	–	–	0.01%	629
2017 Q1	$3.09M	Hold	795,000	–	–	0.01%	644
2016 Q4	$2.97M	Hold	795,000	–	–	0.01%	634
2016 Q3	$3.3M	Sell	795,000 -80,000	-9%	-$379K	0.01%	634
2016 Q2	$4.06M	Hold	875,000	–	–	0.01%	609
2016 Q1	$2.89M	Hold	875,000	–	–	0.01%	632
2015 Q4	$2.98M	Hold	875,000	–	–	0.01%	635
2015 Q3	$3.19M	Hold	875,000	–	–	0.01%	647
2015 Q2	$4.35M	Hold	875,000	–	–	0.01%	648
2015 Q1	$7.03M	Buy	+875,000	New	+$8.28M	0.02%	596

Adage Capital Partners's NVET Position: Q3 2017 in Review

Adage Capital Partners sold out of Nexvet Biopharma plc Ordinary Shares (NVET) in Q3 2017, closing a stake of 795,000 shares — an estimated $5.32M sold.

Adage Capital Partners first reported a position in NVET in Q1 2015 and held it in 10 quarters. The position peaked at $7.03M in Q1 2015. 0 funds tracked by Wall St. Rank hold NVET as of Q3 2017.

Adage Capital Partners reported no remaining Nexvet Biopharma plc Ordinary Shares position as of Q3 2017 after selling out during the quarter.
Adage Capital Partners sold 795,000 Nexvet Biopharma plc Ordinary Shares shares in Q3 2017, an estimated $5.32M.
Adage Capital Partners first reported a position in Nexvet Biopharma plc Ordinary Shares in Q1 2015 and held it in 10 quarters.
Adage Capital Partners's Nexvet Biopharma plc Ordinary Shares position peaked at $7.03M in Q1 2015.
0 funds tracked by Wall St. Rank held Nexvet Biopharma plc Ordinary Shares as of Q3 2017.

Based on Adage Capital Partners's 13F filing for Q3 2017, filed 14 Nov 2017.